» Articles » PMID: 16195243

Envenoming Bites by Kraits: the Biological Basis of Treatment-resistant Neuromuscular Paralysis

Overview
Journal Brain
Specialty Neurology
Date 2005 Oct 1
PMID 16195243
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Beta-bungarotoxin, a neurotoxic phospholipase A2 is a major fraction of the venom of kraits. The toxin was inoculated into one hind limb of young adult rats. The inoculated hind limb was paralysed within 3 h, and remained paralysed for 2 days. The paralysis was associated with the loss of synaptic vesicles from motor nerve terminal boutons, a decline in immunoreactivity of synaptophysin, SNAP-25 and syntaxin, a loss of muscle mass and the upregulation of NaV(1.5) mRNA and protein. Between 3 and 6 h after the inoculation of toxin, some nerve terminal boutons exhibited clear signs of degeneration. Others appeared to be in the process of withdrawing from the synaptic cleft and some boutons were fully enwrapped in terminal Schwann cell processes. By 12 h all muscle fibres were denervated. Re-innervation began at 3 days with the appearance of regenerating nerve terminals, a return of neuromuscular function in some muscles and a progressive increase in the immunoreactivity of synaptophysin, SNAP-25 and syntaxin. Full recovery occurred at 7 days. The data were compared with recently published clinical data on envenoming bites by kraits and by extrapolation we suggest that the acute, reversible denervation caused by beta-bungarotoxin is a credible explanation for the clinically important, profound treatment-resistant neuromuscular paralysis seen in human subjects bitten by these animals.

Citing Articles

Clinical and demographic profiling of snakebite envenomation in a tertiary care centre in northern India.

Sasidharan P, Kaeley N, Mahala P, Jose J, Shankar T, Santhalingan S Int J Emerg Med. 2025; 18(1):50.

PMID: 40065251 PMC: 11892126. DOI: 10.1186/s12245-024-00796-x.


Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial.

Gerardo C, Carter R, Kumar S, Shirazi F, Kotehal S, Akpunonu P BMJ Glob Health. 2024; 9(10).

PMID: 39442939 PMC: 11499837. DOI: 10.1136/bmjgh-2024-015985.


Conotoxins Targeting Voltage-Gated Sodium Ion Channels.

Pei S, Wang N, Mei Z, Zhangsun D, Craik D, McIntosh J Pharmacol Rev. 2024; 76(5):828-845.

PMID: 38914468 PMC: 11331937. DOI: 10.1124/pharmrev.123.000923.


Urgent administration of antivenom following proven krait bites in Southeast Asia irrespective of neurotoxic symptoms.

Blessmann J, Kreuels B PLoS Negl Trop Dis. 2024; 18(4):e0012079.

PMID: 38603643 PMC: 11008851. DOI: 10.1371/journal.pntd.0012079.


Efficacy of a low dose of antivenom for severe neuroparalysis in (common krait) envenomation: a pilot study.

Pannu A, Chand D, Bhalla A, Dhibar D Toxicol Res (Camb). 2024; 13(2):tfae023.

PMID: 38450179 PMC: 10913380. DOI: 10.1093/toxres/tfae023.